Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Podcast

Incidence, Treatment, and Outcomes of Coronary Artery Perforation During PCI: JIC Podcast Episode 2

Deepak Bhatt, MD, MPH, JIC Editor-in-Chief, and Emmanouil S. Brilakis, MD, PhD

 

11/07/2022

Deepak Bhatt, MD, MPH, Editor-in-Chief of the Journal of Invasive Cardiology (JIC), and Emmanouil Brilakis, MD, PhD discuss coronary perforation, a rare but potentially life-threatening complication of PCI. JIC July 2022, Avula et al.

You can also listen to this episode on Spotify and Apple Podcasts!

Drs Bhatt and Brilakis
Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital Heart & Vascular Center, Boston, Massachusetts and Emmanouil S. Brilakis, MD, PhD, Minneapolis Heart Institute, Minne­apolis, Minnesota

Incidence, Treatment, and Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention

Vennela Avula, BSPH; Emmanouil S. Brilakis, MD, PhD; et al.

J INVASIVE CARDIOL 2022;34(7):E499-E504. Epub 2022 June 17.


Advertisement

Advertisement

Advertisement

News

MEETINGS
ACC Quality Summit Highlights Critical Value of ACC Accreditation and NCDR Services
09/06/2024
The American College of Cardiology (ACC) Quality Summit 2024 will take place on September 17-19 in San Antonio, bringing together cardiovascular leaders from across the nation to discuss the value of NCDR services and quality programs.
The American College of Cardiology (ACC) Quality Summit 2024 will take place on September 17-19 in San Antonio, bringing together cardiovascular leaders from across the nation to discuss the value of NCDR services and quality programs.
The American College of...
09/06/2024
Cath Lab Digest
TAVR
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
09/06/2024
Venus-Vitae utilizes the Venus-Endura technology, which integrates multiple anti-calcification techniques, immunogenicity removal technology and 3D force-controlled dehydration technology, providing exceptional durability, biocompatibility,...
Venus-Vitae utilizes the Venus-Endura technology, which integrates multiple anti-calcification techniques, immunogenicity removal technology and 3D force-controlled dehydration technology, providing exceptional durability, biocompatibility,...
Venus-Vitae utilizes the...
09/06/2024
Cath Lab Digest
Risk Factors
Chinese American Immigrants Face Higher Risk of Cardiovascular Disease Depending on Length of Residence and Location in the U.S. 
09/05/2024
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart...
09/05/2024
Cath Lab Digest
Pharmaceutical Therapy
Long-Term Follow-Up Data From Phase 3 Study of Camzyos (mavacamten) Underscores Established Efficacy and Safety Profile in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
09/04/2024
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC...
09/04/2024
Cath Lab Digest
Pharmaceutical Therapy
Late-Breaking Kerendia (finerenone) Investigational Data Show Reduction in Cardiovascular Death and Total Heart Failure Events in Adults with Heart Failure With Mildly Reduced or Preserved Ejection Fraction
09/04/2024
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only...
09/04/2024
Cath Lab Digest
AI
Viz.ai and Cleerly Partner on Heart Disease Evaluation Using Artificial Intelligence
09/04/2024
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the...
09/04/2024
Cath Lab Digest
Radiation Protection
AliMed, Inc. Awarded Vizient Contract for Radiation Protection Products
09/04/2024
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an...
09/04/2024
Cath Lab Digest
Imaging
First U.S. Patient Randomized to CT-Guided PCI in P4 Research Trial Accelerating Innovation with Advanced Cardiovascular Imaging
09/03/2024
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollments in the Precise Procedural and PCI Plan (P4) Research Trial evaluating the potential for advanced cardiovascular imaging to enhance patient care.
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollments in the Precise Procedural and PCI Plan (P4) Research Trial evaluating the potential for advanced cardiovascular imaging to enhance patient care.
Minneapolis Heart Institute...
09/03/2024
Cath Lab Digest
Bioadaptors
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
09/03/2024
The INFINITY-SWEDEHEART Randomized Controlled Trial comparing the novel DynamX® Coronary Bioadaptor System with the contemporary Resolute Onyx™ zotarolimus drug-eluting stent (DES) met its primary endpoint of target lesion failure (TLF)...
The INFINITY-SWEDEHEART Randomized Controlled Trial comparing the novel DynamX® Coronary Bioadaptor System with the contemporary Resolute Onyx™ zotarolimus drug-eluting stent (DES) met its primary endpoint of target lesion failure (TLF)...
The INFINITY-SWEDEHEART...
09/03/2024
Cath Lab Digest
SGLT2 Inhibitors
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack
09/03/2024
EMPACT-MI is the first analysis to determine if it is safe with respect to the kidney to initiate SGLT2 inhibitors in patients during or soon after hospitalization for acute MI. The researchers assessed the therapy’s effects on kidney...
EMPACT-MI is the first analysis to determine if it is safe with respect to the kidney to initiate SGLT2 inhibitors in patients during or soon after hospitalization for acute MI. The researchers assessed the therapy’s effects on kidney...
EMPACT-MI is the first analysis...
09/03/2024
Cath Lab Digest

Advertisement

Advertisement

MEETINGS
ACC Quality Summit Highlights Critical Value of ACC Accreditation and NCDR Services
09/06/2024
The American College of Cardiology (ACC) Quality Summit 2024 will take place on September 17-19 in San Antonio, bringing together cardiovascular leaders from across the nation to discuss the value of NCDR services and quality programs.
The American College of Cardiology (ACC) Quality Summit 2024 will take place on September 17-19 in San Antonio, bringing together cardiovascular leaders from across the nation to discuss the value of NCDR services and quality programs.
The American College of...
09/06/2024
Cath Lab Digest
TAVR
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
09/06/2024
Venus-Vitae utilizes the Venus-Endura technology, which integrates multiple anti-calcification techniques, immunogenicity removal technology and 3D force-controlled dehydration technology, providing exceptional durability, biocompatibility,...
Venus-Vitae utilizes the Venus-Endura technology, which integrates multiple anti-calcification techniques, immunogenicity removal technology and 3D force-controlled dehydration technology, providing exceptional durability, biocompatibility,...
Venus-Vitae utilizes the...
09/06/2024
Cath Lab Digest
Risk Factors
Chinese American Immigrants Face Higher Risk of Cardiovascular Disease Depending on Length of Residence and Location in the U.S. 
09/05/2024
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart...
09/05/2024
Cath Lab Digest
Pharmaceutical Therapy
Long-Term Follow-Up Data From Phase 3 Study of Camzyos (mavacamten) Underscores Established Efficacy and Safety Profile in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
09/04/2024
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC...
09/04/2024
Cath Lab Digest
Pharmaceutical Therapy
Late-Breaking Kerendia (finerenone) Investigational Data Show Reduction in Cardiovascular Death and Total Heart Failure Events in Adults with Heart Failure With Mildly Reduced or Preserved Ejection Fraction
09/04/2024
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only...
09/04/2024
Cath Lab Digest
AI
Viz.ai and Cleerly Partner on Heart Disease Evaluation Using Artificial Intelligence
09/04/2024
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the...
09/04/2024
Cath Lab Digest
Radiation Protection
AliMed, Inc. Awarded Vizient Contract for Radiation Protection Products
09/04/2024
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an...
09/04/2024
Cath Lab Digest
Imaging
First U.S. Patient Randomized to CT-Guided PCI in P4 Research Trial Accelerating Innovation with Advanced Cardiovascular Imaging
09/03/2024
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollments in the Precise Procedural and PCI Plan (P4) Research Trial evaluating the potential for advanced cardiovascular imaging to enhance patient care.
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollments in the Precise Procedural and PCI Plan (P4) Research Trial evaluating the potential for advanced cardiovascular imaging to enhance patient care.
Minneapolis Heart Institute...
09/03/2024
Cath Lab Digest
Bioadaptors
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
09/03/2024
The INFINITY-SWEDEHEART Randomized Controlled Trial comparing the novel DynamX® Coronary Bioadaptor System with the contemporary Resolute Onyx™ zotarolimus drug-eluting stent (DES) met its primary endpoint of target lesion failure (TLF)...
The INFINITY-SWEDEHEART Randomized Controlled Trial comparing the novel DynamX® Coronary Bioadaptor System with the contemporary Resolute Onyx™ zotarolimus drug-eluting stent (DES) met its primary endpoint of target lesion failure (TLF)...
The INFINITY-SWEDEHEART...
09/03/2024
Cath Lab Digest
SGLT2 Inhibitors
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack
09/03/2024
EMPACT-MI is the first analysis to determine if it is safe with respect to the kidney to initiate SGLT2 inhibitors in patients during or soon after hospitalization for acute MI. The researchers assessed the therapy’s effects on kidney...
EMPACT-MI is the first analysis to determine if it is safe with respect to the kidney to initiate SGLT2 inhibitors in patients during or soon after hospitalization for acute MI. The researchers assessed the therapy’s effects on kidney...
EMPACT-MI is the first analysis...
09/03/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement